SSTR1 and oropharynx cancer: Among patients with oral cavity and oropharynx cancer, the disease-free survival rate in the group of patients with both SST and SSTR1 methylation was 48.1% as compared with 81.4% in the other groups (log-rank test, P = 0.028) (Fig. 4D).